

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL STAGE APPLICATION OF

DONALD MANNING

INTERNATIONAL APPLICATION NO: PCT/EP2004/009797

FILED: 2 SEPTEMBER 2004

U.S. APPLICATION NO: Not Yet Known

35 USC §371 DATE: Herewith

FOR: USE OF OXCARBAZEPINE FOR THE TREATMENT OF DIABETIC
NEUROPATHIC PAIN AND THE IMPROVEMENT OF SLEEP

MS: Amendment

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

This paper is being filed within three months of the date of entry of the national stage as set forth in 37 C.F.R. §1.491 of the international application. Therefore, no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-0134.


In accordance with 37 C.F.R. §1.56, applicant wishes to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

The listed references were cited in the international stage search report. Since these references are of record in the instant PCT application PCT/EP2004/009797, copies are not enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Novartis
Corporate Intellectual Property
One Health Plaza, Building 104
East Hanover, NJ 07936-1080
(862) 778-7951

Respectfully submitted,


Peter J. Waibel
Attorney for Applicant
Reg. No. 43,228

Date: 3/1/06

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO. 10/158/3340
33341-US-PCT
APPLICATION NO.
Not Yet Known
APPLICANT
Donald Manning
FILING DATE
Herewith

Group

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	AM	01/32183	5/10/01	WO			<input type="checkbox"/>	<input type="checkbox"/>
	AN	2004/035041	4/29/04	WO			<input type="checkbox"/>	<input type="checkbox"/>
	AO						<input type="checkbox"/>	<input type="checkbox"/>
	AP						<input type="checkbox"/>	<input type="checkbox"/>
	AQ						<input type="checkbox"/>	<input type="checkbox"/>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	AR	Carrazana et al., "Rationale and Evidence for the Use of Oxcarbazepine in Neuropathic Pain", Journal of Pain and Symptom Management, Vol. 25, No. 5, pp. S31-S35 (2003).
	AS	Schmader, "Epidemiology and Impact on Quality of Life and Posttherapeutic Neuralgia", The Clinical Journal of Pain, Vol. 18, No. 6, pp. 350-354 (2002).
	AT	

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.